Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Thymosin-alpha-1

Thymalfasin, Zadaxin, Thymosin α1

Quick Stats
Studies 759
Trials 63
Score 3
1995 pubmed

Immunotherapy with natural interleukins and/or thymosin alpha 1 potently augments T-lymphocyte responses of hydrocortisone-treated aged mice.

Hadden. J W JW; Saha. A A; Sosa. M M; Hadden. E M EM

Key Findings

  • Tα1 alone increased the ability of spleen and thymus cells to respond to immune signals in aged, steroid‑treated mice.
  • Combining Tα1 with a natural cytokine mixture (NCM) further increased spleen weight and the numbers of CD4+ and CD8+ T‑cells.
  • Recombinant IL‑1, IL‑2, or their combination did not produce the same immune‑boosting effects.

Practical Outcomes

  • For biohackers, this study suggests that Tα1 could be a useful supplement for supporting T‑cell function, especially when paired with a broad‑spectrum natural cytokine blend. However, the data are from an animal model, so human dosing, safety, and effectiveness remain unknown. Until clinical trials are available, any self‑experiment should start with very low doses and be monitored closely.

Summary

In old mice whose immune systems were weakened by a steroid, giving them the peptide thymosin‑alpha‑1 (Tα1) – especially together with a mix of natural cytokines – helped their T‑cells bounce back. The treatment boosted the number and activity of both CD4 and CD8 T‑cells in the spleen, although it didn’t affect the thymus size.

Abstract

Cytokines and thymic hormones are thought to play critical roles in the regulation of T-lymphocyte development and function. In an effort to determine the effectiveness of such agents in an immunotherapeutic strategy, we employed aged mice in a hydrocortisone treatment model to generate an immunodeficient state and to study its reconstitution. Mice were given five daily injections of a natural cytokine mixture (NCM), recombinant interleukins (rIL-1, rIL-2) or their combination, thymosin alpha 1 or fraction 5 (T alpha 1, TF5), or the combinations of NCM plus T alpha 1 and of NCM plus TF5. Spleen and thymus weights were obtained and the cellular responses to stimulation in vitro with NCM, IL-1, IL-2 and mitogens (PHA and Con A) were assayed. Both NCM and T alpha 1 in vivo treatment augmented thymocyte and splenocyte in vitro responses to both interleukins and mitogens. Neither treatments with equivalent doses of rIL-1, rIL-2 nor their combination, nor TF5 achieved similar results. Of all the treatments, only NCM plus T alpha 1 augmented spleen weight; none augmented thymus weight. Surface marker analyses of T-lymphocytes and subsets indicate that treatment of mice with NCM plus T alpha 1 increased spleen T-cell numbers of both CD4 and CD8 positive cells significantly. These data indicate that NCM and T alpha 1 alone and in combination may be therapeutically useful to restore T-lymphocyte number or function in secondary immunodeficiency.

Study Information

Provider

pubmed

Year

1995

DOI

10.1016/0192-0561(95)00069-e